Author: Huang Siyu
With the significant increase in the demand for key materials such as therapeutic drugs, testing reagents, and protective equipment after the new crown "Class B and B Control", a number of listed pharmaceutical companies have recently disclosed the progress of fund-raising investment projects and clinical research progress, responding to market concerns about the production of epidemic prevention materials and enterprises Concern about capacity supply.
On the evening of January 2, a number of listed companies issued announcements on major product development, production line construction, and fundraising progress.
Among them, Junshi Biotechnology disclosed the progress of the joint research and development of the new crown drug VV116; Disclosed the progress of fundraising projects.
New crown drug and vaccine development is in full swing
The research and development progress of anti-epidemic products has attracted much attention.
On the evening of January 2, Junshi Biology announced that the oral nucleoside anti-SARS-CoV-2 drug VV116 tablets jointly developed by its holding subsidiary Juntuo Biology and Wangshan Wangshui has completed a comparison with Naimatevir tablets. A phase III clinical study of the combination drug (PAXLOVID) with ritonavir tablets (PAXLOVID) for the early treatment of patients with mild to moderate new coronavirus infection who progressed to severe, including high risk factors for death, and was also carried out in different populations A number of international multi-center phase III clinical studies of VV116.
Frontier Bio, the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the Wuhan Institute of Virology, Chinese Academy of Sciences jointly developed the anti-new coronary pneumonia virus 3CL protease inhibitor FB2001 (Bofutrelvir).
According to the announcement, at present, the company is actively accelerating the phase II/III clinical trial of FB2001 for injection to treat hospitalized patients with new coronavirus infection and the phase II/III clinical trial of FB2001 for aerosol inhalation to treat patients with mild and common new coronavirus infection test.
The approval of the new crown vaccine has also attracted market attention.
CanSino issued an announcement stating that at present, the company’s intramuscular injection of the new crown vaccine has obtained conditional marketing approval in China for people aged 18 and over, and has been approved for sequential booster immunization. License/Conditional Listing.
At the same time, the company's inhaled new crown vaccine has been included in emergency use as a booster shot in China.
At the same time, Sinovac Pharmaceuticals stated that the phase II clinical study of the company's new crown small molecule oral drug SHEN26 capsules successfully completed the enrollment of all subjects.
SHEN26 Capsules is a broad-spectrum and potent novel coronavirus polymerase (RdRp) inhibitor, which has highly effective in vitro inhibitory activity against different novel coronavirus variants.
It is also known that Sunshine Novo's bromhexine hydrochloride oral solution and ibuprofen suspension drops have been approved through the fast-track review process.
The bromhexine hydrochloride oral solution approved this time is the first product in China that has passed the generic drug application and passed the consistency evaluation of generic drugs; the ibuprofen suspension drops approved this time is the first product in China that has passed the "Generic Drug Consistency Evaluation" of pharmaceutical preparation products.
Pharmaceutical companies "riveting" to increase production and guarantee supply
In addition to the research and development of new drugs, in order to cope with the tight supply of medical supplies, many listed pharmaceutical companies have optimized production scheduling, implemented non-stop machine rotation in the workshop, employee rotation, and 7*24-hour production plans to maximize the release of production capacity.
On the evening of January 2, Jichuan Pharmaceutical stated that the current production of Xiaoer Chiqiao Qingre Granules is at full capacity, which can guarantee the production and supply of more than 1 million bags of Xiaoer Chiqiao Qingre Granules per day.
In addition, the company's fundraising project "annual production of 720 million bags of children's Chiqiao Qingre granules" is expected to start debugging and trial production in the second half of 2023.
Guizhou Sanli also stated that the current production capacity utilization rate is close to 200%, which can guarantee the production and supply of more than 200,000 bottles of Kaihoujian spray series products per day.
Moreover, the company's fundraising project "GMP Transformation Phase II Expansion Project" is expected to complete commissioning and start trial production in July 2023. At that time, the company's overall production capacity will be greatly increased to nearly 100 million bottles per year, fully breaking through the production capacity bottleneck.
According to China Business News, recently, Shanghai Pharmaceuticals, a subsidiary of Shanghai Pharmaceuticals, has increased the production schedule of two cold medicines, Anmameimin Tablets and Phenaminokamin Tablets, and doubled the daily output of Phenaminokamin Tablets. Three batches of Ammamine tablets were urgently put into production.
Shanghai Pharmaceutical Guofeng has completed the production of more than 1.7 million boxes of anti-epidemic drugs, and Shanghai Pharmaceutical’s regular drug ibuprofen has a daily production of 1.5 million tablets, and the production cycle has been shortened from 24 days to 13 days.
In addition, the output and production capacity of Kangenba’s products such as Compound Houttuynia Herba Mixture, Acetylcysteine Effervescent Tablets, Compound Amphenamine Capsules, and Ibuprofen have been expanded by 3 to 4 times, and the subsidiary Jiangxi Kangenba Traditional Chinese Medicine Company has resumed production. Started the production of ibuprofen tablets and officially put them on the market, with a daily output of more than 5.7 million tablets.
IPO fundraising projects are accelerated
With the gradual optimization of epidemic control policies, the importance of early diagnosis, late treatment and monitoring of new coronavirus infection through CT and mobile DR products on lung imaging has become prominent.
In this regard, the relevant listed companies disclosed the progress of IPO fundraising projects.
Yirui Technology announced that the Taicang Production Base (Phase II) of the fundraising project "production base construction project" has completed the plant construction, and the Haining Production Base has entered the trial production stage, and the production capacity has climbed in an orderly manner.
"R&D Center Construction Project" Mars1417V3, Mars1717V3 and other general wireless products have entered the mass production stage, which can be used as key components of mobile DR to assist doctors in accurate diagnosis and treatment.
United Imaging, the leading medical imaging company in China, also said that after the completion of the fundraising project "High-end Medical Imaging Equipment Industrialization Fund Project", it will be used to produce high-end XR, CT, PET/CT, MR and PET/MR series products, among which XR and CT products can be used for disease diagnosis of the new crown epidemic. The orderly promotion of fundraising projects will help improve the level of product epidemic diagnosis and alleviate the shortage of medical equipment.
In response to the tight supply of medical supplies such as antigen detection reagents, a number of detection and diagnosis-related companies launched fundraising projects to release production capacity.
Rejing Biology announced that it will adjust and enable the company's raised capital investment project "in vitro diagnostic reagents with an annual output of 12 million pieces, 850 supporting equipment production bases and R&D centers", and the production line of this project will be converted to expand production capacity.
Aotai Bio also stated that as of now, the company's fundraising project "industrialization upgrading and technological transformation project with an annual output of 265 million in vitro diagnostic reagents" has been put into production.
There are also some pharmaceutical companies using refinancing methods to improve production and operation capabilities and lay out a safety line for epidemic prevention.
Among them, Lukang Pharmaceutical disclosed a non-public offering reminder announcement that it plans to raise 1.2 billion for the expansion of anti-viral, anti-infection, and pain-reducing drugs.
search
copy